{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:53:53Z","timestamp":1781632433060,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/1-002-01\/503-11-001-19-00"],"award-info":[{"award-number":["503\/1-002-01\/503-11-001-19-00"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel diseases (IBD) are often associated with intestinal fibrosis. There is increased interest in new methods for managing intestinal fibrosis, among which the endocannabinoid system (ECS) is an interesting therapeutic target. The primary purpose of the study was to evaluate the effect of CB1\/2 agonist, WIN 55,212-2 (WIN) on expression of fibrosis regulatory proteins: alpha smooth muscle Actin 2 (ACTA2), Collagen I (COLIA1), Fibronectin 1 (FN1) and SMAD family member 3 (SMAD3) in a mice model of dextran sulfate sodium (DSS)-induced intestinal fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Chronic intestinal fibrosis was induced by oral administration of 1.5% DSS in rotation with tap water for 3 weeks in three cycles. WIN was administered intraperitoneally, once daily starting from day 10th and continued every other day until day 77th. The expression of genes encoding ACTA2, COL1A1, FN1, SMAD3, Col1a1, Fn1 both in mouse and human colon, was assessed with real-time PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found lower relative expression of genes encoding fibrosis regulatory proteins in colonic mucosa of mice treated with WIN than in inflamed mice: ACTA2 (\u201351%), COL1A1 (\u201344%), FN1 (\u201360%), and SMAD3 (\u201322%). Human colonic mucosal patients with UC showed higher expression of COL1A1 (+\u200957%) and SMAD3 (+\u200934%) compared to healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results show that regulation of ECS activity may play a role in the inhibition of intestinal fibrosis in IBD and appears as a potential therapeutic target in patients at high risk of developing strictures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00822-0","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:30Z","timestamp":1769411970000},"page":"479-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model"],"prefix":"10.1007","volume":"78","author":[{"given":"Zofia","family":"Misztal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0459-0642","authenticated-orcid":false,"given":"Maria","family":"Wo\u0142yniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-1807","authenticated-orcid":false,"given":"Ewa","family":"Ma\u0142ecka-Wojciesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6997-4925","authenticated-orcid":false,"given":"Adam","family":"Fabisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.dld.2023.04.003","volume":"55","author":"J Park","year":"2023","unstructured":"Park J, Jeong GH, Song M, Yon D, Lee S, Koyanagi A, et al. The global, Regional, and National burden of inflammatory bowel diseases, 1990\u20132019: A systematic analysis for the global burden of disease study 2019. Dig Liver Disease. 2023;55:1352\u20139.","journal-title":"Dig Liver Disease"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/00365521.2014.968863","volume":"50","author":"G Latella","year":"2014","unstructured":"Latella G, Di Gregorio J, Flati V, Rieder F, Lawrance IC. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2014;50:53\u201365.","journal-title":"Scand J Gastroenterol"},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.trsl.2019.03.005","volume":"209","author":"J Li","year":"2019","unstructured":"Li J, Mao R, Kurada S, Wang J, Lin S, Chandra J, et al. Pathogenesis of fibrostenosing crohn\u2019s disease. Translational Res. 2019;209:39\u201354.","journal-title":"Translational Res"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.gastro.2019.05.072","volume":"162","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Rieder F, Feagan BG, Higgins PDR, Pan\u00e9s J, Maaser C, et al. Challenges in the Pathophysiology, Diagnosis, and management of intestinal fibrosis in inflammatory bowel disease. Gastroenterology. 2022;162:26\u201331.","journal-title":"Gastroenterology"},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The endocannabinoid system: A potential target for the treatment of various diseases. Int J Mol Sci. 2021;22:9472.","journal-title":"Int J Mol Sci"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pharmthera.2009.12.005","volume":"126","author":"AA Izzo","year":"2010","unstructured":"Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21\u201338.","journal-title":"Pharmacol Ther"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1365-2036.2005.02648.x","volume":"22","author":"M Duncan","year":"2005","unstructured":"Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther. 2005;22:667\u201383.","journal-title":"Aliment Pharmacol Ther"},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bcp.2018.07.048","volume":"157","author":"JA Uranga","year":"2018","unstructured":"Uranga JA, Vera G, Abalo R. Cannabinoid Pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018;157:134\u201347.","journal-title":"Biochem Pharmacol"},{"key":"822_CR9","first-page":"134","volume":"33","author":"A Perisetti","year":"2020","unstructured":"Perisetti A, Rimu AH, Khan SA, Bansal P, Goyal H. Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. 2020;33:134\u201344.","journal-title":"Ann Gastroenterol"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/JCMM.13359","volume":"22","author":"M Pesce","year":"2018","unstructured":"Pesce M, D\u2019Alessandro A, Borrelli O, Gigli S, Seguella L, Cuomo R, Esposito G, Sarnelli G. Endocannabinoid-Related compounds in Gastrointestinal diseases. J Cell Mol Med. 2018;22:706\u201315. https:\/\/doi.org\/10.1111\/JCMM.13359.","journal-title":"J Cell Mol Med"},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/jcmm.13359","volume":"22","author":"M Pesce","year":"2018","unstructured":"Pesce M, D\u2019Alessandro A, Borrelli O, Gigli S, Seguella L, Cuomo R, et al. Endocannabinoid-related compounds in Gastrointestinal diseases. J Cell Mol Med. 2018;22:706\u201315.","journal-title":"J Cell Mol Med"},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI200419465","volume":"113","author":"F Massa","year":"2004","unstructured":"Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202\u20139.","journal-title":"J Clin Invest"},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/art.24395","volume":"60","author":"A Akhmetshina","year":"2009","unstructured":"Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 2009;60:1129\u201336.","journal-title":"Arthritis Rheum"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/ard.2010.137539","volume":"70","author":"E Balistreri","year":"2011","unstructured":"Balistreri E, Garcia-Gonzalez E, Selvi E, Akhmetshina A, Palumbo K, Lorenzini S, e tal. The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model. Ann Rheum Dis. 2011;70:695\u20139.","journal-title":"Ann Rheum Dis"},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"166753","DOI":"10.1016\/j.bbadis.2023.166753","volume":"1869","author":"A Krzy\u017cewska","year":"2023","unstructured":"Krzy\u017cewska A, Baranowska-Kuczko M, Kasacka I, Koz\u0142owska H. Cannabidiol alleviates right ventricular fibrosis by inhibiting the transforming growth factor \u03b2 pathway in monocrotaline-induced pulmonary hypertension in rats. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166753.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s10753-022-01688-z","volume":"45","author":"Q He","year":"2022","unstructured":"He Q, Zhang W, Zhang J, Deng Y, Cannabinoid Analogue WIN. 55212-2 protects Paraquat-Induced lung injury and enhances macrophage M2 polarization. Inflammation. 2022;45:2256\u201367.","journal-title":"Inflammation"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijid.2017.03.008","volume":"59","author":"E Dai","year":"2017","unstructured":"Dai E, Zhang L, Ye L, Wan S, Feng L, Qi Q, et al. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B. Int J Infect Dis. 2017;59:124\u201330.","journal-title":"Int J Infect Dis"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"e92281","DOI":"10.1172\/jci.insight.92281","volume":"2","author":"R Cinar","year":"2017","unstructured":"Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, et al. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight. 2017;2:e92281.","journal-title":"JCI Insight"},{"key":"822_CR19","doi-asserted-by":"publisher","first-page":"e3001532","DOI":"10.1371\/journal.pbio.3001532","volume":"20","author":"GJ Jasso","year":"2022","unstructured":"Jasso GJ, Jaiswal A, Varma M, Laszewski T, Grauel A, Omar A, et al. Colon stroma mediates an inflammation-driven fibroblastic response controlling matrix remodeling and healing. PLoS Biol. 2022;20:e3001532.","journal-title":"PLoS Biol"},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"e00082","DOI":"10.14309\/ctg.0000000000000082","volume":"10","author":"MD Gundersen","year":"2019","unstructured":"Gundersen MD, Goll R, Fenton CG, Anderssen E, S\u00f8rbye SW, Florholmen JR, et al. Fibrosis mediators in the colonic mucosa of acute and healed ulcerative colitis. Clin Transl Gastroenterol. 2019;10:e00082.","journal-title":"Clin Transl Gastroenterol"},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"jjae132","DOI":"10.1093\/ecco-jcc\/jjae132","volume":"19","author":"MF Nan\u00ec","year":"2025","unstructured":"Nan\u00ec MF, Pagano E, De Cicco P, Lucariello G, Cattaneo F, Tropeano FP, et al. Pharmacological Inhibition of N-Acylethanolamine acid amidase (NAAA) mitigates intestinal fibrosis through modulation of macrophage activity. J Crohns Colitis. 2025;19:jjae132.","journal-title":"J Crohns Colitis"},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/ijms25010165","volume":"25","author":"I Palenca","year":"2023","unstructured":"Palenca I, Seguella L, Zilli A, Basili Franzin S, Del Re A, Pepi F, et al. Intrarectal administration of adelmidrol plus hyaluronic acid gel ameliorates experimental colitis in mice and inhibits Pro-Inflammatory response in ex vivo cultured biopsies derived from ulcerative colitis-Affected patients. Int J Mol Sci. 2023;25:165.","journal-title":"Int J Mol Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00822-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00822-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:08:05Z","timestamp":1781629685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00822-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00822-0","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal protocols were approved by the Medical University of Lodz Animal Care Committee (Protocol No. 5\/LB227\/2021). The human part of the study was approved by the Bioethics Committee of the Medical University of Lodz (Approval No. RNN\/67\/22\/KE). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}